UPCC 54419: A Phase II Open-label Multicenter Study | Clinical Research Studies Listing

Recruiting

99 years or below

All

1 Location

Brief description of study

This study enrolls subjects with relapsed or refractory CD30-positive Peripheral T-cell Lymphoma (PTCL) or Transformed Mycosis Fungoides (TMF). The purpose of this study is to learn about the effects of a research medicine called AFM13 and to see how well AFM13 is tolerated. This study is divided in three cohorts, depending on diagnosis and the level of a tumor marker. About 145 participants are expected to participate in this study around the world.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 01 Jun 2021. Study ID: 835016

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 54419: A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

Brief description of study

Eligibility of study

Find a site